Luigi Cappannoli

Cardiologist • PhD Program • Interventional Cardiology and Heart Failure • Università Cattolica del Sacro Cuore • A. Gemelli Policlinic, Rome 🇮🇹

[Davide Capodanno @DFCapodanno]

The PROTECT IV trial is a prospective, multicenter, randomized study evaluating whether routine Impella CP support during high-risk PCI improves outcomes in patients with complex CAD and LVEF ≤40% (n=1,252) deemed unsuitable for surgery. Patients are randomized 1:1 to PCI with Impella CP versus PCI with or without IABP. The primary endpoint is a composite of death, stroke, MI, revascularization, advanced heart failure therapy, or cardiovascular hospitalization at 3 years. https://t.co/x3Khemg00s

[Luigi Cappannoli @LCappannoli]

💊 Our latest meta-analysis of 12,602 patients dives deep into the use of colchicine in ACS: no significant reduction in MACE, but timing, dosing, and patient selection may matter more than we thought. https://t.co/ohg9JrfBFn

#Cardiology #Inflammation #Colchicine #ACS

[EHJ Editor-in-Chief @ehj_ed]

Practical Guide to Right Heart Catheterization: Enhancing Diagnosis and Treatment in Heart Failure!

#EHJ #cardiotwitter #right #heart #failure @ESC_journals @escardio

https://t.co/X0MqiS4if6

[JORGE FERNANDEZ @drjorfer]

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction? | Cardiovascular Diabetology | Full Text🔴✅ https://t.co/PFEObGyvjY

[Luigi Cappannoli @LCappannoli]

The importance of #multimodalityimaging combining #3DCTscan and @fluoroscopy is depicted in this rare case of "Percutaneous retrieval of a subcutaneous contraceptive device migrated in pulmonary circulation"
⬇️⬇️💥

https://t.co/sA2EJpmaws

@BURZOTTA_F
@ciropollio
@carlotrani

[EHJ Editor-in-Chief @ehj_ed]

The impact of routine invasive vs. conservative management in older patients with non-ST-elevation acute coronary syndrome. Read the latest meta-analysis in #EHJ.
https://t.co/D7qlxCy34Z
#older #NSTEACS #cardiotwitter @ESC_Journals @escardio

[Davide Capodanno @DFCapodanno]

EuroIntervention is pleased to share with you our free State-of-the-Art papers collection: high-level insights on general topics of interventional interest, written by top-class international experts, with many more to come. Do you have topics to suggest? https://t.co/T8YD94rviu

[EuroIntervention @EuroInterventio]

This #EIJBestOf State-of-the-Art paper reviewed the management of cardiogenic shock, especially after acute myocardial infarction, with a major focus on current treatments and practices based on the latest clinical literature. https://t.co/hGt6UJX1b1

[FRANCESCO BURZOTTA @BURZOTTA_F]

#Impella use varies across continents. Yet, Europeans started using it earlier gaining lot of practical experience. Team effort led to this comprehensive EHJ Supplement reporting shared best practices on each pt management step.
https://t.co/Ejk2huaCKr.
@ESC_journals

[Frontiers in Cardiovascular Medicine @FrontCVMedicine]

New Research: Multicolor flow cytometry on pericardial effusion for a prompt diagnosis and treatment of hematological malignancies with heart involvement: Background

Malignancies represent 15–50% of total causes of pericardial effusions… https://t.co/MhcQbwHMs4 #cardiovascular

[European Society of Cardiology Journals @ESC_Journals]

ECPELLA versus #ECMO in #CardiogenicShock – do the potential benefits of this unloading strategy outweigh the increased complications? https://t.co/jKmpoNNZLY

#EHJQCCO #CathLab @cpgale3 @diogoasantosfer

[Luigi Cappannoli @LCappannoli]

🚨Just released in @FrontCVMedicine🚨 Our paper ⬇ about the role of Multicolor Flow Cytometry performed on #pericardialfluid samples to detect hematological malignancies!
With Professors Massimo Imazio, @DDamario, @ehj_ed and @tommasosanna_MD
https://t.co/fD5BK8udCs

[Luigi Cappannoli @LCappannoli]

Postgraduate Course in Heart Failure -London just finished! #heartfailure #pchf #london #graduation 💔🇬🇧🇨🇭 https://t.co/k4DpHjeova

[Julia Seller @JuliaSellerm]

Top3 heart failure trials in September 2022: #CardioTwitter

🥇 Albuminuria as a marker of systemic congestion in HF @ESC_Journals

🥈Randomized trial of LBB vs Biventricular Pacing for CRT @JACCJournals

🥉Optimal pharmacologic treatment of HFpEF and HFmrEF @JAMACardio

[EuroIntervention @EuroInterventio]

❗NEW ISSUE❗ STATE-OF-THE-ART on RECANALISATION OF CORONARY CHRONIC TOTAL OCCLUSION: a detailed overview of the history, indications and treatment strategies for CTO recanalisation. #EAPCI #cardiotwitter https://t.co/Il3VSvvQxI

[Luigi Cappannoli @LCappannoli]

#esc #esc2022 #ESCCongress https://t.co/PFJnQzUrga

[FRANCESCO BURZOTTA @BURZOTTA_F]

Happy to share: first ONYX FRONTIER #DES implanted in Europe 🇪🇺. Subocclusive lesion of angulated LCX causing #NSTEMI in a high #bleeding risk pt. Smooth #radialfirst #PCI.
Time to thank all the people working daily with us in the cath lab under great direction of Carlo Trani !

[Cristina Aurigemma @CristinaAuri17]

🙎🏻‍♂️73 yo EF 27 LM-LAD disease in left dominance. Surgical turndown. During PCI at each dilatation loss of pulsatility and complete Impella support with late pulsatility recovery. Impella single access protected PCI: good procedure planning @AntonioMariaLe2 #CHIP #surgicalturndown

[Luigi Cappannoli @LCappannoli]

Finally out our paper just published in #EHJCaseReports ‘Here comes the story of the Hurricane’: a case report of AL cardiac amyloidosis and myocardial bridging. @DDamario @peppefercil @AttilioRestivo @tommasosanna_MD and Professor Filippo Crea @ehj_ed
https://t.co/q24NcxaEw5

[EHJ Editor-in-Chief @ehj_ed]

2021 Impact Factors have been released & we are delighted to announce that our IF has increased to 35.855! We are very grateful to all of our authors, editors, reviewers and readers. THANK YOU! ❤️

Submit your best papers to #EHJ now! https://t.co/yAAjmUdt8D

@escardio